Oxford Trial hold will not affect on Indian trials: Serum Institute. The trial of the Covid-19 vaccine being developed by Oxford University and AstraZeneca PLC was halted after a volunteer in the UK became ill. In India, this vaccine is being developed by the Serum Institute of India (SII), Pune. Following the developments in Britain, a statement has been issued by the Serum Institute of India (SII) regarding vaccine trials in India. The situation in this regard has also been clarified by the Oxford Jenner Institute in London.
Indian vaccine trials will not be affected: Poonawala
SII Chief Executive Officer (CEO) Adar Poonawala said in a statement on Wednesday, “Nothing unpleasant has happened during the vaccine trials in India.” The incident in Britain will not have any effect on the Indian vaccine trial carried out by the Serum Institute. ”
The Oxford Vaccine AZD122 (ChAdOx1 nCoV-19) is being tested by the Serum Institute. In India, this vaccine is also known as covishield.
Poonawala said, “The reaction that has been reported is not directly related to the vaccine. The person who reacted had a neurological condition already. It is normal for such incidents to occur during a vaccine trial. ” Poonawala also clarified that the production timelines of the institute were on the same schedule as planned.
Break a routine action on trials: Oxford Jenner Institute
“Our standard review process triggered a study pause on vaccination, as part of the ongoing Randomized Controlled Global Trials for Corona Virus Vaccine. Oxford Jenner Institute in London. So that security data can be reviewed. This is a routine action. This happens when one of the studies shows a disease whose cause may not be obvious. It is being investigated, but we make sure to maintain the integrity of the trials. In general, trial disease can occur accidentally, but it must be carefully reviewed independently. We are committed to protecting our participants (Volunteers) and there is no compromise with the high standards of conduct in our stews. ”
Oxford Trial hold will not affect on Indian trials: Serum Institute
The first and second successful phases of the trial have raised hopes and many tie-ups around the world for mass production of the vaccine. In the third phase, the vaccine trials were expanded to the United States, Brazil, South America and India.
It is reported that during this phase, a volunteer in Britain was diagnosed with transverse myelitis, an inflammatory syndrome affecting the spinal cord, for which viral infection may be responsible. An independent investigation is being conducted to find the cause. The decision to resume the trial will be taken by the Medicine and Healthcare Products Regulatory Agency (MHRA).